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137Cs source, respectively. The spatial resolution of this 
detector so far has been determined to be about 5 mm, using 
the k-nearest-neighbour algorithm (k-NN) [1]. 
Moreover, the Compton camera has been commissioned at 
different particle beam facilities. The time-of-flight (TOF) 
capability of the system was evaluated at the Garching 
Tandem accelerator, using a 20 MeV pulsed (400 ns) deuteron 
beam hitting a water phantom, showing prompt γ rays well 
separated from the slower neutrons. The camera was further 
tested with different clinical proton beams from the research 
area of the University Proton Therapy Dresden (100, 160 and 
225 MeV) stopping in either a water or a PMMA phantom, as 
indicated in Fig.1. For all three proton beam energies, the 
analysis of the prompt γ energy versus the TOF showed no 
significant neutron background. The Compton electron 
energy loss was extracted from each DSSSD layer, showing a 
gradual sequential increase of the energy loss from the first 
to the last layer.  
 
 
Figure 1: The Compton camera, enclosed in a Faraday light 
tight cage, is placed under 90o relative to the proton beam 
that hits a water phantom (here at the OncoRay facility, 
Universitäts Protonen Therapie Dresden). 
 
Conclusion: A Compton camera is under development in 
Garching, designed for online ion beam range verification via 
prompt γ detection. The monolithic LaBr3 detector was 
characterized in the laboratory exhibiting excellent energy 
and time resolution as well as a sufficient position resolution. 
The Compton camera was commissioned with a low-energy 
pulsed deuteron beam at the Garching Tandem accelerator 
and with high-energy clinical proton beams at the OncoRay 
facility, Dresden.  
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Purpose: Particle therapy provide a more favorable dose 
distribution compared to x-rays, but limited focus has been 
on the actual biological responses. Effects of carbon ion 
radiation in experimental tumor models has been 
investigated in a limited number of studies, the majority of 
these with tumor growth delay as biological endpoint. To 
elucidate the biological variation in radiation response in 
particle therapy, more in vivo studies are needed. The aim of 
the present study was to compare the biological 
effectiveness of carbon ions relative to x-rays between the 
clinical relevant endpoint tumor control and normal tissue 
damage, both acute and late effects. 
Materials and Methods: CDF1 mice with C3H mouse mammary 
carcinoma placed subcutaneously on the foot of the right 
hind limb were irradiated with single fractions of either 
photons or 12C ions, using a 30-mm spread-out Bragg peak. 
Endpoint of the study was local control (no tumor recurrence 
within 90 days). For the acute skin reaction, non-tumor 
bearing CDF1 mice were irradiated with a comparable 
radiation scheme, and monitored for acute skin damage. Late 
radiation induced fibrosis was measured up to 322 days 
following treatment.  
Results: The TCD50 (dose producing tumor control in 50% of 
mice) values with 95% confidence interval were 29.7 (25.37- 
34.78) Gy for C ions and 43.94 (39.24- 49.2) Gy for photons. 
The corresponding RBE values were 1.48 (1.28-1.72). For 
acute skin damage the MDD50 (dose to produce moist 
desquamation in 50% of mice) values with 95% confidence 
interval were 26.34 (22.99-30.19) Gy for C ions and 35.84 
(32.94-38.98) Gy for photons, resulting in a RBE of 1.36 
(1.20-1.45). For late radiation-induced fibrosis the FD50 (dose 
to produce severe fibrosis in 50% of the mice) with 95% 
confidence interval were 26.5 (23.1 – 30.3) Gy for carbon ions 
and 39.8 (37.8 – 41.8) Gy for photons, with a RBE of 1.50 
(1.33 – 1.69).  
Conclusions: We have established TCD50, MDD50 and FD50 
values for local tumor control and normal tissue damage and 
the corresponding RBE values for carbon ions in a mouse 
model. The observed RBE values were very similar for tumor 
response, acute skin damage and late RIF when irradiated 
with large doses of high- linear energy transfer (LET) carbon 
ions. This study add information to the variation in biological 
effectiveness in different tumor and normal tissue models. 
(Acta Oncologica, In Press) 
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The Proton Therapy Facility at TRIUMF is now in routine 
operation treating ocular tumours using 74 MeV protons 
extracted from the 500 MeV H- cyclotron. In this work, the 
feasibility of using PET scanning for proton dose monitoring is 
investigated. Different lucite phantoms have been irradiated 
with a raw Bragg peak and a spread out Bragg peak of 74 MeV 
and scanned using two PET scanners at UBC hospital. 
Simulation programs GEANT4 and FLUKA are being used to 
validate against experimental measurements. GEANT4 has 
been coupled with EXFOR cross section data of proton 
induced reactions to calculate the axial activity of the 
phantoms. Despite the very simple setup, significant 
discrepancies between the codes have been observed for the 
activity profiles of 11C and 15O and 13N, whereas the beam 
range in lucite has been found to have good agreement.  
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